← Back to Search

Receptor Tyrosine Kinase Inhibitor

SLC-391 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by SignalChem Lifesciences Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Summary

This trial is testing a new drug called SLC-391, which aims to block a protein that helps cancer cells grow. It is for patients with advanced solid tumors who haven't responded to other treatments. The study will check if the drug is safe and find the best dose to use.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Maximum Tolerated Dose of SLC-391
Number of Participants with Adverse Events (AEs) as assessed by NCI-CTCAE v5.0
Secondary study objectives
Area under the plasma concentration versus time curve (AUC) of SLC-391
Maximum Observed Plasma Concentration (Cmax)
Number of Participants with Clinically Significant Changes From Baseline in Laboratory Parameters
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dose escalationExperimental Treatment1 Intervention
The starting dose will be 25 mg/day and subsequent doses will be determined after an internal review by Data Review Committee of all available safety, PK and PD data from the minimum required number of subjects who complete cycle 1. All dose-escalation decisions and the rationale for progressing to the next cohort will be documented. A subject may continue treatment with SLC-391 in 21-day cycles until the treatment discontinuation criteria are met.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SLC-391
2022
Completed Phase 1
~60

Find a Location

Who is running the clinical trial?

SignalChem Lifesciences CorporationLead Sponsor
3 Previous Clinical Trials
126 Total Patients Enrolled
Zaihui Zhang, PhDStudy DirectorSignalChem Lifesciences Corporation
1 Previous Clinical Trials
98 Total Patients Enrolled
~6 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top